Novo Nordisk announced headline results from the 68-week REIMAGINE 2 phase 3 trial evaluating once-weekly CagriSema (fixed-dose cagrilintide plus semaglutide) in 2,728 patients with type 2 diabetes. From a mean baseline HbA1c of 8.2%, the 2.4 mg/2.4 mg dose delivered a reduction of 1.91 percentage points versus 1.76 points for semaglutide alone. Mean weight loss reached 14.2% compared with 10.2% with semaglutide. Gastrointestinal events were the most common adverse reactions and were generally mild to moderate. Citi analysts noted these results were largely baked into forecasts, shifting investor focus to upcoming head-to-head trials against Eli Lilly’s tirzepatide in 2026 and cardiovascular outcomes data in 2027.

Nichols & Pratt Advisers LLP MA increased its holding by 8,935 shares to 500,991 shares in the third quarter, making Novo Nordisk its 22nd largest position at approximately $27.8 million. True Wealth Design more than tripled its stake to 443 shares, while NewSquare Capital and several smaller advisors initiated or raised positions totaling under 500 shares each. Collectively, hedge funds and other institutional investors hold 11.54% of Novo Nordisk’s shares, reflecting ongoing confidence in its mid-term growth trajectory despite intense competition in the obesity and diabetes market.

Among 23 analysts covering the company, seven maintain Buy ratings, twelve Hold and three Sell, resulting in a consensus Hold. Argus and Citigroup reaffirmed neutral assessments in December and January, respectively, while Goldman Sachs reiterated a Buy view in late January. The average target stands at $57.79, implying limited upside relative to recent trading multiples. Market-based metrics show a price-to-earnings ratio near 17 and a dividend yield around 1.8%, underscoring balanced risk-reward for patient investors.